Maryland Medicaid Pharmacy Program Fax: (866) 440-9345 Phone: (800) 932-3918

Xgeva® Prior Authorization Form



Patient's Information:			DATE:	
NAME:			DOB:	
Recipient's Maryland Medicaid Number:			SEX: □ M □ F	
Preso	criber	's Information:		
NAME	E:		NPI#	
Phone	e #		Fax #	
Conta	act Pe	erson for this Request:		
NAME	E:	Phone:	Fax:	
Υ	N		Xgeva [®]	
		Does the patient have a diagnosis of giant cell tumor of the bone?		
٥	Does the patient have a tumor that is either recurrent, unresectable or where surgical resection is likely to cause severe morbidity?			
		Is the patient a skeletally mature adolescent with a weight > 45 kg?		
		Does that patient have a diagnosis of bone metastases from solid tumors?		
		Does the patient have a diagnosis of hypercalcemia of malignancy?		
		Is the hypercalcemia refractory to intrav	enous bisphosphonate therapy?	
		Does the patient have any contraindications to Xgeva® therapy (hypocalcemia, hypersensitivity to ingredients)?		
		Is patient currently receiving Prolia [®] ? Xgeva [®] includes the same active ingredient (denosumab) found in Prolia [®] . Patients receiving Xgeva [®] should not take Prolia [®] .		
Dose: Xgeva® 120 mg subcutaneously every 4 weeks, with additional doses on days 8 and 15 of the first month of treatment. Xgeva® 120 mg subcutaneously every 4 weeks.				
Directions for use:				
I certify that all the above information is accurate and will be made available for audit if requested.				
Prescriber's Signature			Date	

Fax this completed form to 866-440-9345. Incomplete forms will not be reviewed.